Claudio Pietra Selected Research

netupitant

1/2018	Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT3 Antagonist, Palonosetron and With the NK1 Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew).
1/2018	Corrigendum: Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT3 Antagonist, Palonosetron and With the NK1 Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew).
1/2016	Profile of Antiemetic Activity of Netupitant Alone or in Combination with Palonosetron and Dexamethasone in Ferrets and Suncus murinus (House Musk Shrew).
10/2014	Synergistic effect of 5-hydroxytryptamine 3 and neurokinin 1 receptor antagonism in rodent models of somatic and visceral pain.
5/2014	Role of neurokinin 1 receptors in dextran sulfate-induced colitis: studies with gene-deleted mice and the selective receptor antagonist netupitant.
9/2012	In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant.
8/2012	Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claudio Pietra Research Topics

Disease

7	Vomiting 01/2020 - 11/2010
5	Neoplasms (Cancer) 01/2021 - 12/2014
5	Body Weight (Weight, Body) 01/2019 - 01/2016
4	Nausea 01/2018 - 11/2010
3	Hypersensitivity (Allergy) 01/2020 - 10/2014
3	Hyperalgesia 01/2020 - 08/2003
3	Obesity 12/2018 - 12/2017
3	Anorexia 05/2017 - 12/2014
3	Cachexia 05/2017 - 12/2014
2	Motion Sickness (Airsickness) 01/2020 - 01/2018
2	Neuralgia (Stump Neuralgia) 01/2020 - 08/2003
2	Ileus 01/2019 - 01/2012
2	Metabolic Diseases (Metabolic Disease) 12/2018 - 12/2017
2	Pain (Aches) 10/2014 - 08/2003
1	Lymphoma (Lymphomas) 01/2021
1	Nociceptive Pain 01/2020
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Hypoglycemia (Reactive Hypoglycemia) 01/2020
1	Inflammation (Inflammations) 01/2020
1	Insulin Resistance 01/2020
1	Starvation 01/2020
1	Feeding and Eating Disorders (Eating Disorder) 01/2020
1	Parkinson Disease (Parkinson's Disease) 01/2019
1	Type 2 Diabetes Mellitus (MODY) 12/2018
1	Prader-Willi Syndrome (Syndrome, Prader-Willi) 12/2018
1	Hyperphagia (Overeating) 12/2018
1	Weight Gain 01/2018
1	Diabetes Mellitus 12/2017
1	AIDS-Related Complex (ARC) 01/2016
1	Hepatocellular Carcinoma (Hepatoma) 01/2016
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 10/2014
1	Visceral Pain 10/2014
1	Colitis 05/2014
1	Overactive Urinary Bladder (Overactive Bladder) 10/2012
1	Gastroparesis 01/2012
1	Amnesia (Dissociative Amnesia) 05/2004
1	Alzheimer Disease (Alzheimer's Disease) 05/2004

Drug/Important Bio-Agent (IBA)

10	Ghrelin ReceptorsIBA 01/2020 - 01/2012
9	HM01IBA 01/2020 - 01/2016
8	GhrelinIBA 01/2020 - 01/2012
7	netupitantIBA 01/2018 - 08/2012
6	Palonosetron (Aloxi)FDA Link 01/2018 - 11/2010
5	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 10/2014 - 08/2012
4	Cisplatin (Platino)FDA LinkGeneric 12/2018 - 01/2016
3	LigandsIBA 01/2020 - 11/2010
3	muskIBA 01/2020 - 01/2018
3	Serotonin 5-HT3 Receptor AntagonistsIBA 01/2018 - 10/2014
3	AntiemeticsIBA 01/2018 - 01/2016
3	Serotonin (5 Hydroxytryptamine)IBA 01/2016 - 11/2010
3	Substance PIBA 01/2016 - 11/2010
2	ipamorelinIBA 01/2020 - 01/2012
2	Acetic Acid (Vinegar)FDA LinkGeneric 01/2020 - 10/2014
2	Hormones (Hormone)IBA 01/2020 - 12/2018
2	Copper Sulfate (Sulfate, Copper)FDA Link 01/2018 - 01/2016
2	EmeticsIBA 01/2018 - 01/2016
2	TachykininsIBA 01/2016 - 08/2012
1	Histone Deacetylase InhibitorsIBA 01/2021
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	SB939 compoundIBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	Lapatinib (GW572016)FDA Link 01/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020
1	Insulin (Novolin)FDA Link 01/2020
1	acyl-ghrelinIBA 01/2020
1	Oxidopamine (6 Hydroxydopamine)IBA 01/2019
1	Bortezomib (Velcade)FDA Link 12/2018
1	Insulin-Like Growth Factor I (IGF-1)IBA 12/2018
1	Blood Glucose (Blood Sugar)IBA 12/2018
1	SecretagoguesIBA 12/2018
1	Nicotine FDA Link 01/2018
1	Urea (Carbamide)FDA LinkGeneric 01/2018
1	LipidsIBA 12/2017
1	Glucose (Dextrose)FDA LinkGeneric 12/2017
1	Interleukin-6 (Interleukin 6)IBA 05/2017
1	CytokinesIBA 05/2017
1	Aprepitant (Emend)FDA Link 01/2016
1	Apomorphine FDA Link 01/2016
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2016
1	Morphine (MS Contin)FDA LinkGeneric 01/2016
1	Ondansetron (Zofran)FDA LinkGeneric 01/2016
1	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 01/2016
1	anamorelinIBA 12/2014
1	Analgesics (Analgesic Drugs)IBA 10/2014
1	Dextran SulfateIBA 05/2014
1	SolutionsIBA 05/2014
1	Cholinergic Agents (Cholinergics)IBA 01/2012
1	PeptidomimeticsIBA 01/2012
1	Scopolamine (Hyoscine)FDA Link 05/2004
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 05/2004
1	CHF 2819IBA 05/2004
1	Nerve Growth Factor (NGF)IBA 05/2004
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2004
1	Acetylcholine (Acetylcholine Chloride)FDA Link 05/2004
1	ganstigmineIBA 05/2004
1	CarrageenanIBA 08/2003
1	Memantine (Namenda)FDA Link 08/2003

Therapy/Procedure

7	Drug Therapy (Chemotherapy) 01/2020 - 11/2010
1	Therapeutics 01/2019
1	Aftercare (After-Treatment) 01/2018
1	Oral Administration 05/2014